Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure

Wakaya Fujiwara, Yasuchika Kato, Mutsuharu Hayashi, Yoshinori Sugishita, Satoshi Okumura, Masataka Yoshinaga, Tomoya Ishiguro, Ryo Yamada, Sayano Ueda, Masahide Harada, Hiroyuki Naruse, Junichi Ishii, Yukio Ozaki, Hideo Izawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Although cardiac sarcoidosis is associated with poor prognosis, diagnosis of the disease is challenging and the sensitivity and specificity of diagnostic modalities are limited. This study was performed to evaluate the potential of serum microRNAs (miRNAs) as diagnostic biomarkers for cardiac sarcoidosis. Methods: We performed genome-wide expression profiling for 2565 miRNAs (Human-miRNA ver.21) using peripheral blood samples from 5 patients with cardiac sarcoidosis (61 ± 9 years) and 3 healthy controls (54 ± 7 years). From this screening study, we selected 12 miRNAs that were significantly related to cardiac sarcoidosis. Next, we performed real-time polymerase chain reaction (PCR) on blood samples from 15 new patients with cardiac sarcoidosis and 4 healthy controls to quantify the expression of these 12 miRNAs. Results: In the screening study, 12 miRNAs were differentially expressed (p < 0.01) in all 5 patients with cardiac sarcoidosis, showing greater fold-change values (>4 or <0.25) compared with the expression in the 3 healthy controls. Analysis of the real-time PCR for blood samples from the other 15 patients and 4 controls using Mann–Whitney U tests revealed that the expression of miR-126 and miR-223 was significantly higher in the patients than in the healthy individuals. However, there were no differences in the expressions of miRNA-126 and miR-223 between patients with only cardiac lesions and those with extra-cardiac lesions. Conclusions: Our results demonstrate the potential of serum miR-126 and miR-223 as new-generation biomarkers for the differential diagnosis of cardiac sarcoidosis in patients with heart failure.

Original languageEnglish
Pages (from-to)452-457
Number of pages6
JournalJournal of cardiology
Volume72
Issue number6
DOIs
Publication statusPublished - 01-12-2018

Fingerprint

Sarcoidosis
MicroRNAs
Heart Failure
Biomarkers
Serum
Real-Time Polymerase Chain Reaction
Differential Diagnosis
Genome
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Fujiwara, Wakaya ; Kato, Yasuchika ; Hayashi, Mutsuharu ; Sugishita, Yoshinori ; Okumura, Satoshi ; Yoshinaga, Masataka ; Ishiguro, Tomoya ; Yamada, Ryo ; Ueda, Sayano ; Harada, Masahide ; Naruse, Hiroyuki ; Ishii, Junichi ; Ozaki, Yukio ; Izawa, Hideo. / Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure. In: Journal of cardiology. 2018 ; Vol. 72, No. 6. pp. 452-457.
@article{3f17645ee3374e82a8f44ca1976eadef,
title = "Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure",
abstract = "Background: Although cardiac sarcoidosis is associated with poor prognosis, diagnosis of the disease is challenging and the sensitivity and specificity of diagnostic modalities are limited. This study was performed to evaluate the potential of serum microRNAs (miRNAs) as diagnostic biomarkers for cardiac sarcoidosis. Methods: We performed genome-wide expression profiling for 2565 miRNAs (Human-miRNA ver.21) using peripheral blood samples from 5 patients with cardiac sarcoidosis (61 ± 9 years) and 3 healthy controls (54 ± 7 years). From this screening study, we selected 12 miRNAs that were significantly related to cardiac sarcoidosis. Next, we performed real-time polymerase chain reaction (PCR) on blood samples from 15 new patients with cardiac sarcoidosis and 4 healthy controls to quantify the expression of these 12 miRNAs. Results: In the screening study, 12 miRNAs were differentially expressed (p < 0.01) in all 5 patients with cardiac sarcoidosis, showing greater fold-change values (>4 or <0.25) compared with the expression in the 3 healthy controls. Analysis of the real-time PCR for blood samples from the other 15 patients and 4 controls using Mann–Whitney U tests revealed that the expression of miR-126 and miR-223 was significantly higher in the patients than in the healthy individuals. However, there were no differences in the expressions of miRNA-126 and miR-223 between patients with only cardiac lesions and those with extra-cardiac lesions. Conclusions: Our results demonstrate the potential of serum miR-126 and miR-223 as new-generation biomarkers for the differential diagnosis of cardiac sarcoidosis in patients with heart failure.",
author = "Wakaya Fujiwara and Yasuchika Kato and Mutsuharu Hayashi and Yoshinori Sugishita and Satoshi Okumura and Masataka Yoshinaga and Tomoya Ishiguro and Ryo Yamada and Sayano Ueda and Masahide Harada and Hiroyuki Naruse and Junichi Ishii and Yukio Ozaki and Hideo Izawa",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jjcc.2018.06.004",
language = "English",
volume = "72",
pages = "452--457",
journal = "Journal of Cardiology",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "6",

}

Fujiwara, W, Kato, Y, Hayashi, M, Sugishita, Y, Okumura, S, Yoshinaga, M, Ishiguro, T, Yamada, R, Ueda, S, Harada, M, Naruse, H, Ishii, J, Ozaki, Y & Izawa, H 2018, 'Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure', Journal of cardiology, vol. 72, no. 6, pp. 452-457. https://doi.org/10.1016/j.jjcc.2018.06.004

Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure. / Fujiwara, Wakaya; Kato, Yasuchika; Hayashi, Mutsuharu; Sugishita, Yoshinori; Okumura, Satoshi; Yoshinaga, Masataka; Ishiguro, Tomoya; Yamada, Ryo; Ueda, Sayano; Harada, Masahide; Naruse, Hiroyuki; Ishii, Junichi; Ozaki, Yukio; Izawa, Hideo.

In: Journal of cardiology, Vol. 72, No. 6, 01.12.2018, p. 452-457.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure

AU - Fujiwara, Wakaya

AU - Kato, Yasuchika

AU - Hayashi, Mutsuharu

AU - Sugishita, Yoshinori

AU - Okumura, Satoshi

AU - Yoshinaga, Masataka

AU - Ishiguro, Tomoya

AU - Yamada, Ryo

AU - Ueda, Sayano

AU - Harada, Masahide

AU - Naruse, Hiroyuki

AU - Ishii, Junichi

AU - Ozaki, Yukio

AU - Izawa, Hideo

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Although cardiac sarcoidosis is associated with poor prognosis, diagnosis of the disease is challenging and the sensitivity and specificity of diagnostic modalities are limited. This study was performed to evaluate the potential of serum microRNAs (miRNAs) as diagnostic biomarkers for cardiac sarcoidosis. Methods: We performed genome-wide expression profiling for 2565 miRNAs (Human-miRNA ver.21) using peripheral blood samples from 5 patients with cardiac sarcoidosis (61 ± 9 years) and 3 healthy controls (54 ± 7 years). From this screening study, we selected 12 miRNAs that were significantly related to cardiac sarcoidosis. Next, we performed real-time polymerase chain reaction (PCR) on blood samples from 15 new patients with cardiac sarcoidosis and 4 healthy controls to quantify the expression of these 12 miRNAs. Results: In the screening study, 12 miRNAs were differentially expressed (p < 0.01) in all 5 patients with cardiac sarcoidosis, showing greater fold-change values (>4 or <0.25) compared with the expression in the 3 healthy controls. Analysis of the real-time PCR for blood samples from the other 15 patients and 4 controls using Mann–Whitney U tests revealed that the expression of miR-126 and miR-223 was significantly higher in the patients than in the healthy individuals. However, there were no differences in the expressions of miRNA-126 and miR-223 between patients with only cardiac lesions and those with extra-cardiac lesions. Conclusions: Our results demonstrate the potential of serum miR-126 and miR-223 as new-generation biomarkers for the differential diagnosis of cardiac sarcoidosis in patients with heart failure.

AB - Background: Although cardiac sarcoidosis is associated with poor prognosis, diagnosis of the disease is challenging and the sensitivity and specificity of diagnostic modalities are limited. This study was performed to evaluate the potential of serum microRNAs (miRNAs) as diagnostic biomarkers for cardiac sarcoidosis. Methods: We performed genome-wide expression profiling for 2565 miRNAs (Human-miRNA ver.21) using peripheral blood samples from 5 patients with cardiac sarcoidosis (61 ± 9 years) and 3 healthy controls (54 ± 7 years). From this screening study, we selected 12 miRNAs that were significantly related to cardiac sarcoidosis. Next, we performed real-time polymerase chain reaction (PCR) on blood samples from 15 new patients with cardiac sarcoidosis and 4 healthy controls to quantify the expression of these 12 miRNAs. Results: In the screening study, 12 miRNAs were differentially expressed (p < 0.01) in all 5 patients with cardiac sarcoidosis, showing greater fold-change values (>4 or <0.25) compared with the expression in the 3 healthy controls. Analysis of the real-time PCR for blood samples from the other 15 patients and 4 controls using Mann–Whitney U tests revealed that the expression of miR-126 and miR-223 was significantly higher in the patients than in the healthy individuals. However, there were no differences in the expressions of miRNA-126 and miR-223 between patients with only cardiac lesions and those with extra-cardiac lesions. Conclusions: Our results demonstrate the potential of serum miR-126 and miR-223 as new-generation biomarkers for the differential diagnosis of cardiac sarcoidosis in patients with heart failure.

UR - http://www.scopus.com/inward/record.url?scp=85050289577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050289577&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2018.06.004

DO - 10.1016/j.jjcc.2018.06.004

M3 - Article

C2 - 30054123

AN - SCOPUS:85050289577

VL - 72

SP - 452

EP - 457

JO - Journal of Cardiology

JF - Journal of Cardiology

SN - 0914-5087

IS - 6

ER -